Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 9/20 | 0.78 |
| ▸ | CDK1 | P06493 | 8/20 | 0.78 |
| ▸ | CCNB1 | P14635 | 7/20 | 0.78 |
| ▸ | CCNA2 | P20248 | 7/20 | 0.78 |
| ▸ | CDK2 | P24941 | 7/20 | 0.78 |
| ▸ | CCNA1 | P78396 | 7/20 | 0.78 |
| ▸ | MGMT | P16455 | 6/20 | 0.78 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 0.78 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 6-O-Benzylguanine SCHEMBL61740 | 0.88 | PIN1 (1.00) | PIN1CDK1CCNB1CCNA2CDK2 | |
| 6-O-Benzylguanine SCHEMBL31517079 | 0.88 | PIN1 (1.00) | PIN1CDK1CCNB1CCNA2CDK2 | |
| 6-O-Benzylguanine SCHEMBL4631744 | 0.86 | PIN1 (0.97) | PIN1CDK1CCNB1CCNA2CDK2 | |
| 6-O-Benzylguanine SCHEMBL4869639 | 0.82 | PIN1 (0.88) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL23124359 | 0.78 | MGMT (0.81) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL29749175 | 0.78 | MGMT (0.81) | PIN1CDK1CCNB1CCNA2CDK2 | |
| 6-O-Benzylguanine SCHEMBL10916361 | 0.77 | PIN1 (0.76) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL29460225 | 0.76 | CDK1 (0.66) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL9682546 | 0.76 | CDK1 (0.66) | PIN1CDK1CCNB1CCNA2CDK2 | |
| SCHEMBL3297931 | 0.75 | PIN1 (1.00) | PIN1CDK1CCNB1CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104788485-A | Process for preparing antiviral agent | BRISTOL MYERS SQUIBB CO | 2015-07-22 | — | — | CN | disclosed |
| CN-102675355-B | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2015-05-06 | — | — | CN | disclosed |
| CN-101899063-B | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2012-12-12 | — | — | CN | disclosed |
| EP-1644384-B1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR | BRISTOL MYERS SQUIBB CO (US) | 2012-10-31 | — | — | EP | disclosed |
| CN-102675355-A | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2012-09-19 | — | — | CN | disclosed |
| EP-2433941-A1 | Process for isolating the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | Bristol-Myers Squibb Company (US) | 2012-03-28 | — | — | EP | disclosed |
| CN-101130543-B | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO | 2011-06-08 | — | — | CN | disclosed |
| CN-101899063-A | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL MYERS SQUIBB CO | 2010-12-01 | — | — | CN | disclosed |
| CN-101130552-B | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO | 2010-07-28 | — | — | CN | disclosed |
| US-7550619-B2 | Intermediates in the preparation of the antiviral agent [1S-(1α, 3α, 4β)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxmethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-23 | — | — | US | disclosed |
| CN-100379746-C | Process for the preparation of the antiviral agent [ 1S- (1 α,3 α,4 β) ] -2-amino-1, 9-dihydro-9- [ 4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl ] -6H-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2008-04-09 | — | — | CN | disclosed |
| CN-101130552-A | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2008-02-27 | — | — | CN | disclosed |
| CN-101130543-A | Process for preparing the antiviral agent [1s-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6h-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2008-02-27 | — | — | CN | disclosed |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | CHAN YEUNG Y | 2006-05-18 | — | — | US | disclosed |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | PENDRI YADAGIRI R | 2006-05-18 | — | — | US | disclosed |
| US-7034152-B2 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1644384-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | Bristol-Myers Squibb Company (US) | 2006-04-12 | — | — | EP | disclosed |
| CN-1747959-A | Process for the preparation of the antiviral agent [ 1S- (1 α, 3 α, 4 β) ] -2-amino-1, 9-dihydro-9- [ 4-hydroxy-3- (hydroxymethyl) -2-methylenecyclopentyl ] -6H-purin-6-one | BRISTOL MYERS SQUIBB CO (US) | 2006-03-15 | — | — | CN | disclosed |
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-30 | — | — | US | disclosed |
| WO-2004052310-A2 | PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192912-A1 | Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | PIN1 4218/4885CDK1 1762/4885CCNB1 1551/4885 |
| US-20060106216-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | PIN1 4133/4885CDK1 1666/4885CCNB1 1631/4885 |
| US-20060106215-A1 | Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one | SAMHD1, NUDT1, ENTPD1 | PIN1 4133/4885CDK1 1666/4885CCNB1 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.